Sponsors (7)
The bill seeks to enhance medical-product safety, regulatory cooperation, and export opportunities by establishing an overseas FDA presence, trading off additional taxpayer expense, potential diplomatic/security complexity, and the risk of diverting domestic regulatory resources.
Patients (including those with chronic conditions) and U.S. health systems: imported medical products are more likely to meet FDA manufacturing standards because foreign manufacturers will adopt FDA-conforming good manufacturing practices, reducing the risk of unsafe or poor-quality products.
Hospitals, patients, and public-health authorities: stronger regulatory partnership abroad improves surveillance and emergency coordination, supporting faster cross-border responses to product-safety issues and public-health threats.
U.S. biopharma firms and small exporters: clearer FDA engagement and feedback on R&D and manufacturing creates easier market-entry pathways and potential for increased trade and collaboration with Abraham Accords countries.
Hospitals and patients: domestic FDA capacity and attention could be diverted to support the overseas office, potentially reducing oversight or enforcement at home.
Taxpayers: creating and staffing a new overseas FDA office will require public funds for setup and ongoing operations, imposing additional government spending without a specified appropriation.
Federal employees, state governments, and diplomatic/security stakeholders: situating an FDA office abroad could raise diplomatic and security costs, require adherence to security recommendations, and limit some activities or increase operational complexity.
Based on analysis of 2 sections of legislative text.
Creates an FDA Abraham Accords Office abroad to provide regulatory technical assistance and share U.S. regulatory pathways with Accords countries.
Official title: To amend the Federal Food, Drug, and Cosmetic Act to establish an Abraham Accords Office within Food and Drug Administration, and for other purposes.
Introduced March 3, 2025 by Diana Harshbarger · Last progress March 3, 2025
Creates an Abraham Accords Office inside the Food and Drug Administration to be located in an Abraham Accords country and headed by a director. The Office will provide technical assistance and regulatory cooperation with partner countries—sharing information on U.S. regulatory pathways, good manufacturing practices, and feedback on R&D and manufacturing of FDA-regulated products—and must be established within two years with a Congress report due within three years.